浸润性乳腺癌或导管原位癌患者中低分次放疗的使用增加:谁被落下?
该研究基于2004至2020年美国国家癌症数据库,纳入928034例早期浸润性乳腺癌和330964例导管原位癌保乳术后患者,分析低分次全乳放疗的使用趋势及相关因素。结果显示,浸润性乳腺癌患者低分次放疗使用率从2004年的0.7%显著增至2020年的63.9%,导管原位癌患者从0.4%增至56.6%。黑人患者、社区癌症项目、年轻年龄、阳性淋巴结、较大肿瘤、低容量项目及机构位置与低分次放疗采用不足相关。
要点
- 浸润性乳腺癌患者低分次全乳放疗使用率从2004年0.7%增至2020年63.9%,导管原位癌患者从0.4%增至56.6%。
- 黑人浸润性乳腺癌患者接受低分次放疗的调整比值比(AOR)为0.81(95%CI 0.77-0.85),低于白人患者。
- 社区癌症项目浸润性乳腺癌患者AOR为0.80(95%CI 0.77-0.84),导管原位癌患者AOR为0.87(95%CI 0.79-0.96),均低于学术/研究项目。
核心结论
- 保乳术后患者低分次全乳放疗使用率从2004年至2020年显著增加,在美国可最终被视为标准治疗。
- 患者和机构亚组间存在低分次放疗采用的显著差异,减少差异有潜力进一步降低医疗成本并改善患者生活质量。
研究设计与样本
- 基于2004至2020年美国国家癌症数据库的回顾性分析,纳入928034例早期浸润性乳腺癌和330964例导管原位癌保乳术后患者。
- 低分次全乳放疗定义为每次2.5-3.33 Gy,常规分次全乳放疗定义为每次1.8-2.0 Gy。
- 采用广义线性模型(对数链接和二项分布)评估低分次放疗使用趋势,采用多因素logistic回归分析2018至2020年诊断患者中与低分次放疗使用相关的因素。
主要发现
- 浸润性乳腺癌患者低分次放疗使用率从2004年的0.7%显著增至2020年的63.9%。
- 导管原位癌患者低分次放疗使用率从2004年的0.4%显著增至2020年的56.6%。
- 浸润性乳腺癌患者中,黑人患者接受低分次放疗的可能性低于白人患者(AOR 0.81;95%CI 0.77-0.85)。
- 浸润性乳腺癌患者中,社区癌症项目给予低分次放疗的可能性低于学术/研究项目(AOR 0.80;95%CI 0.77-0.84)。
- 导管原位癌患者中,社区癌症项目给予低分次放疗的可能性低于学术/研究项目(AOR 0.87;95%CI 0.79-0.96)。
临床怎么用
- 原文结论认为低分次全乳放疗在美国可最终被视为标准治疗。
- 原文指出减少低分次放疗采用差异有潜力进一步降低医疗成本并改善患者生活质量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aimed to update the trend of hypofractionated whole-breast irradiation (HF-WBI) use over time in the US and examine factors associated with lack of HF-WBI adoption for patients with early-stage invasive breast cancer (IBC) or ductal carcinoma in situ (DCIS) undergoing a lumpectomy. METHODS AND MATERIALS: Among patients who underwent a lumpectomy, we identified 928,034 patients with early-stage IBC and 330,964 patients with DCIS in the 2004 to 2020 National Cancer Database. We defined HF-WBI as 2.5-3.33 Gy/fraction to the breast and conventionally fractionated WBI as 1.8-2.0 Gy/fraction. We evaluated the trend of HF-WBI utilization using a generalized linear model with the log link and binomial distribution. Factors associated with HF-WBI utilization were assessed using multivariable logistic regression in patients diagnosed between 2018 and 2020. RESULTS: Among patients with IBC, HF-WBI use has significantly increased from 0.7% in 2004 to 63.9% in 2020. Similarly, HF-WBI usage among patients with DCIS has also increased significantly from 0.4% in 2004 to 56.6% in 2020. Black patients with IBC were less likely than White patients to receive HF-WBI (adjusted odds ratio [AOR] 0.81; 95% CI, 0.77-0.85). Community cancer programs were less likely to administer HF-WBI to patients with IBC (AOR, 0.80; 95% CI, 0.77-0.84) and to those with DCIS (AOR, 0.87; 95% CI, 0.79-0.96) than academic/research programs. Younger age, positive nodes, larger tumor size, low volume programs, and facility location were also associated with lack of HF-WBI adoption in both patient cohorts. CONCLUSIONS: HF-WBI utilization among postlumpectomy patients has significantly increased from 2004 to 2020 and can finally be considered standard of care in the US. We found substantial disparities in adoption within patient and facility subgroups. Reducing disparities in HF-WBI adoption has the potential to further alleviate health care costs while improving patients' quality of life.
引用
- Booth S, Freeman JQ, Li JL, et al. Increase in Hypofractionated Radiation Therapy Among Patients with Invasive Breast Cancer or Ductal Carcinoma In Situ: Who is Left Behind? Pract Radiat Oncol. 2024. PMID: 38685449. doi:10.1016/j.prro.2024.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。